Home/Biosimilar Atlas/Companies/Prestige Biopharma

Prestige Biopharma

Biosimilar developer, Singapore. 1 development product across 1 molecule: trastuzumab.

FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product0 of 7markets1candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
TrastuzumabTuznue / Hervelous HD201·withdrawn·····0/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists two comparative trials sponsored by Prestige Biopharma for two molecules: bevacizumab, trastuzumab. Candidates without an approval yet in the seven markets: HD204.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
BevacizumabHD204Prestige BiopharmaAvastinPhase 3Comparative efficacyActive, not recruitingNov 2019Jul 2024no approval in the seven marketsNCT03390686
TrastuzumabHD201Prestige BiopharmaHerceptinPhase 3Comparative efficacyCompletedFeb 2018Apr 2019Tuznue / HervelousNCT03013504

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Prestige Biopharma, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

AmgenOne shared molecule: trastuzumab8 molecules in its portfolioBiocadOne shared molecule: trastuzumab3 molecules in its portfolioBiocon BiologicsOne shared molecule: trastuzumab9 molecules in its portfolioCelltrionOne shared molecule: trastuzumab10 molecules in its portfolioCuraTeQ BiologicsOne shared molecule: trastuzumab4 molecules in its portfolioDr. Reddy's LaboratoriesOne shared molecule: trastuzumab6 molecules in its portfolio

Chronology

Compare Prestige Biopharma with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.